Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

523
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

952
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
952
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

787
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
787
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

443
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
443

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood-based RNA-Seq of 5412 individuals with rare disease identifies new candidate diagnoses in the National Genomic Research Library.

medRxiv : the preprint server for health sciences·2026
Same author

CKDu-AGRI Study-a population-based cross-sectional study of chronic kidney disease and chronic kidney disease of unknown aetiology among agricultural workers in Tamil Nadu, India.

The Lancet regional health. Southeast Asia·2025
Same author

Evaluation of validity and reliability of quantitative Cervical Vertebral Maturation Index (QCVMI): A cross-sectional study.

International orthodontics·2025
Same author

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

NPJ precision oncology·2025
Same author

Hemophagocytic lymphohistiocytosis (HLH) secondary to tuberculosis: A case series.

The Indian journal of tuberculosis·2025
Same author

Redefining Vaginal Agenesis Management: A Comprehensive Review.

Cureus·2025

Related Experiment Video

Updated: Mar 3, 2026

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

682

Therapy in diabetic dyslipidemia.

Uma Maheswari1

  • 1Department of Pharmacology, VIPER, Tumkur, Karnataka, India.

Indian Journal of Pharmacology
|March 2, 2026
PubMed
Summary

Combination therapy with saroglitazar and gemfibrozil effectively manages diabetic dyslipidemia by improving lipid profiles and insulin levels. This approach shows promise for treating type 2 diabetes mellitus (T2DM) and associated cardiovascular risks.

Keywords:
Diabeticsdyslipidemiagemfibrozilperoxisome proliferator-activated receptor-alpha-α/γ agonistsaroglitazar and high-density lipoprotein

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

2.5K

Related Experiment Videos

Last Updated: Mar 3, 2026

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

682
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

2.5K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiovascular Medicine

Background:

  • Diabetics face elevated cardiovascular risk, exacerbated by dyslipidemia.
  • Diabetic dyslipidemia involves abnormal triglyceride, LDL, and HDL levels.
  • This condition increases the propensity for lipoprotein abnormalities.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of combined saroglitazar and gemfibrozil.
  • To assess the safety profile of this combination therapy.
  • To address unmet needs in type 2 diabetes mellitus (T2DM) and diabetic dyslipidemia management.

Main Methods:

  • Selected potent doses of saroglitazar and gemfibrozil from a pilot study.
  • Experimental rats were divided into five groups (six animals per group).

Main Results:

  • Combination therapy significantly decreased lipid profiles and atherogenic index.
  • Histopathological studies indicated improvements in organ health.
  • Insulin levels were favorably affected by the combination therapy.
  • The combination demonstrated superior therapeutic efficacy compared to individual drugs.

Conclusions:

  • Saroglitazar and gemfibrozil combination therapy exhibits a favorable safety profile.
  • This combination may serve as a novel therapeutic agent for T2DM and diabetic dyslipidemia.
  • The findings suggest a potential solution for unmet clinical needs in this patient population.